Menu

 

Analysis

Implications of “not me” drugs for health systems: lessons from age related macular degeneration

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2941 (Published 1 May 2012)
Cite this as: BMJ 2012;344:e2941

Related articles

Research: Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study

Published 4 July 2012; BMJ 345 doi: 10.1136/bmj.e4203

Letter: The scientific community should lobby to be able to apply for drug licences

Published 22 May 2012; BMJ 344 doi: 10.1136/bmj.e3553

Editor's Choice: Avastin versus Lucentis

Published 2 May 2012; BMJ 344 doi: 10.1136/bmj.e3162

Feature: Why using Avastin for eye disease is so difficult

Published 1 May 2012; BMJ 344 doi: 10.1136/bmj.e3012

Editorial: Anti-vascular endothelial growth factor treatment for eye diseases

Published 1 May 2012; BMJ 344 doi: 10.1136/bmj.e2970

News: Novartis takes legal action over trusts’ advice to use bevacizumab for wet AMD

Published 24 April 2012; BMJ 344 doi: 10.1136/bmj.e2959

Research: Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

Published 11 June 2010; BMJ 340 doi: 10.1136/bmj.c2459

Why using Avastin for eye disease is so difficult

Anti-vascular endothelial growth factor treatment for eye diseases

Data supplement

Web Extra

Published

Web Extra

Published

Web Extra

Published

See more

Endgames: Selection bias versus allocation bias

Published 24 May 2013; BMJ 346 doi: 10.1136/bmj.f3345

Letter: BMJ shortlisted trial of Edwards-SAPIEN valve does not include all randomised patients

Published 22 May 2013; BMJ 346 doi: 10.1136/bmj.f3229

Letter: Let’s act on the best available evidence on obesity

Published 22 May 2013; BMJ 346 doi: 10.1136/bmj.f3015

This article has been cited by other articles:

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls